AR119681A1 - Métodos de tratamiento del cáncer de mama con tucatinib - Google Patents
Métodos de tratamiento del cáncer de mama con tucatinibInfo
- Publication number
- AR119681A1 AR119681A1 ARP200100202A ARP200100202A AR119681A1 AR 119681 A1 AR119681 A1 AR 119681A1 AR P200100202 A ARP200100202 A AR P200100202A AR P200100202 A ARP200100202 A AR P200100202A AR 119681 A1 AR119681 A1 AR 119681A1
- Authority
- AR
- Argentina
- Prior art keywords
- tucatinib
- breast cancer
- treatment
- methods
- cancer
- Prior art date
Links
- SDEAXTCZPQIFQM-UHFFFAOYSA-N 6-n-(4,4-dimethyl-5h-1,3-oxazol-2-yl)-4-n-[3-methyl-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]quinazoline-4,6-diamine Chemical compound C=1C=C(OC2=CC3=NC=NN3C=C2)C(C)=CC=1NC(C1=C2)=NC=NC1=CC=C2NC1=NC(C)(C)CO1 SDEAXTCZPQIFQM-UHFFFAOYSA-N 0.000 title abstract 3
- 206010006187 Breast cancer Diseases 0.000 title abstract 3
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 3
- 229950003463 tucatinib Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962797854P | 2019-01-28 | 2019-01-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119681A1 true AR119681A1 (es) | 2022-01-05 |
Family
ID=69740562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200100202A AR119681A1 (es) | 2019-01-28 | 2020-01-27 | Métodos de tratamiento del cáncer de mama con tucatinib |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220193076A1 (enExample) |
| EP (1) | EP3917533A1 (enExample) |
| JP (1) | JP2022523045A (enExample) |
| KR (1) | KR20210119498A (enExample) |
| CN (1) | CN113613656A (enExample) |
| AR (1) | AR119681A1 (enExample) |
| AU (1) | AU2020215551A1 (enExample) |
| CA (1) | CA3126279A1 (enExample) |
| IL (1) | IL284850A (enExample) |
| MX (1) | MX2021008834A (enExample) |
| SG (1) | SG11202107488PA (enExample) |
| TW (1) | TW202042820A (enExample) |
| WO (1) | WO2020159822A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7328151B2 (ja) | 2017-04-28 | 2023-08-16 | シージェン インコーポレイテッド | Ｈｅｒ２陽性がんの処置 |
| US20220125877A1 (en) * | 2019-07-10 | 2022-04-28 | Sun Yat-Sen University | Method for treating colorectal cancer |
| MX2023003406A (es) * | 2020-09-28 | 2023-03-31 | Seagen Inc | Metodos de tratamiento de tumores solidos impulsados por alteraciones de her2 con tucatinib en combinacion con un anticuerpo anti-her2. |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CN117243959A (zh) * | 2022-10-13 | 2023-12-19 | 山东大学 | 治疗骨质疏松的方法和药物组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
| US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
| US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
| WO1993017668A1 (en) | 1992-03-12 | 1993-09-16 | Alkermes Controlled Therapeutics, Inc. | Controlled release acth containing microspheres |
| US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
| US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
| JP7328151B2 (ja) * | 2017-04-28 | 2023-08-16 | シージェン インコーポレイテッド | Ｈｅｒ２陽性がんの処置 |
-
2020
- 2020-01-21 TW TW109102121A patent/TW202042820A/zh unknown
- 2020-01-24 KR KR1020217027147A patent/KR20210119498A/ko not_active Withdrawn
- 2020-01-24 CA CA3126279A patent/CA3126279A1/en active Pending
- 2020-01-24 SG SG11202107488PA patent/SG11202107488PA/en unknown
- 2020-01-24 JP JP2021543165A patent/JP2022523045A/ja active Pending
- 2020-01-24 US US17/310,212 patent/US20220193076A1/en not_active Abandoned
- 2020-01-24 MX MX2021008834A patent/MX2021008834A/es unknown
- 2020-01-24 CN CN202080022864.7A patent/CN113613656A/zh active Pending
- 2020-01-24 AU AU2020215551A patent/AU2020215551A1/en not_active Abandoned
- 2020-01-24 EP EP20708761.0A patent/EP3917533A1/en not_active Withdrawn
- 2020-01-24 WO PCT/US2020/014953 patent/WO2020159822A1/en not_active Ceased
- 2020-01-27 AR ARP200100202A patent/AR119681A1/es not_active Application Discontinuation
-
2021
- 2021-07-14 IL IL284850A patent/IL284850A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020159822A1 (en) | 2020-08-06 |
| IL284850A (en) | 2021-08-31 |
| EP3917533A1 (en) | 2021-12-08 |
| US20220193076A1 (en) | 2022-06-23 |
| KR20210119498A (ko) | 2021-10-05 |
| AU2020215551A1 (en) | 2021-08-05 |
| SG11202107488PA (en) | 2021-08-30 |
| MX2021008834A (es) | 2021-09-28 |
| JP2022523045A (ja) | 2022-04-21 |
| CN113613656A (zh) | 2021-11-05 |
| TW202042820A (zh) | 2020-12-01 |
| CA3126279A1 (en) | 2020-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020015255A2 (es) | Métodos y composiciones para tratar el cáncer | |
| CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
| CL2023003068A1 (es) | Compuestos, composiciones y métodos para el tratamiento de trastornos | |
| AR119681A1 (es) | Métodos de tratamiento del cáncer de mama con tucatinib | |
| CO2020013599A2 (es) | Piridazinonas como inhibidoras de parp7 | |
| CO2021001912A2 (es) | Composiciones anti-cd112r y métodos | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CL2019002895A1 (es) | Inhibidores de pd-1/pd-l1. | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| MX2023007841A (es) | Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer. | |
| MX389683B (es) | Composiciones terapeuticas, combinaciones y metodos de uso | |
| MX2019010040A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| CL2017000080A1 (es) | Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| MX2019015204A (es) | Uso del anticuerpo anti-cd70 argx-110 para el tratamiento de leucemia mieloide aguda. | |
| MX392461B (es) | Moduladores de receptores estrogénicos | |
| CL2021001260A1 (es) | Anticuerpos anti-sirpa humanizados | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| MX2018005233A (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. | |
| BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
| MX2021002215A (es) | Derivados de tetrahidropiridopirimidina como moduladores de ahr. | |
| CO2017000552A2 (es) | Bifenil amidas con grupos éter modificados como inhibidores de hsp90 e inductores de hsp70 | |
| PH12017501879A1 (en) | Methods for treating cancer | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| MX2024007360A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |